Panoftalmitis

01Pathophysiology

Panophthalmitis represents the most severe end of the intraocular infection spectrum. Unlike endophthalmitis, which is confined to the intraocular cavities (vitreous and aqueous humor), panophthalmitis describes purulent inflammation involving all three coats of the eye (sclera, uvea, retina) along with extension into the orbital tissues. This distinction matters because the presence of orbital signs (proptosis, ophthalmoplegia, lid edema) on the vignette is the cardinal feature that separates panophthalmitis from endophthalmitis on examinations.

The infection reaches the eye through two main routes. The exogenous route accounts for most cases and follows direct inoculation of organisms after penetrating trauma, intraocular surgery, or perforation of an infected corneal ulcer. The endogenous route occurs through hematogenous seeding in patients with bacteremia, fungemia, infective endocarditis, urinary tract infection, liver abscess (classically Klebsiella pneumoniae in diabetics), or in intravenous drug users.

Once organisms enter the eye, they multiply rapidly in the avascular vitreous, which lacks robust immune surveillance. Bacterial toxins and host inflammatory response cause liquefaction of intraocular tissues. As the infection breaches the sclera, it extends into Tenon's capsule and orbital fat, producing the orbital inflammatory signs that define this condition. Bacillus cereus infection following soil-contaminated penetrating trauma is the most aggressive form and can destroy the eye within 24 to 48 hours.

The patient's complaints map directly onto these mechanisms. Severe pain results from stretching of pain fibers in the sclera and uvea by suppurative material under pressure. Vision loss is due to clouding of ocular media by inflammatory cells and toxic damage to the retina and optic nerve. Proptosis and limited eye movements arise from orbital fat involvement and inflammation around the extraocular muscles. Systemic features such as fever and malaise reflect either the underlying bacteremia (in endogenous cases) or absorption of bacterial toxins.

A point that often appears as a distractor: in panophthalmitis, the inflammation has already crossed beyond the globe, so visual prognosis is poor and the immediate threat is spread to the cavernous sinus and brain through emissary veins. Recognizing this danger drives the aggressive management approach.

02Classification and Clinical Manifestation

03Diagnostic Workup

The diagnostic approach to suspected panophthalmitis begins at the bedside. Panophthalmitis is fundamentally a clinical diagnosis, and treatment must not be delayed while awaiting investigations. Once the typical features (severe pain, proptosis, hypopyon, ophthalmoplegia, near-total vision loss) are identified in a patient with the appropriate risk profile, the immediate priority shifts to obtaining material for culture and starting antibiotics.

The best initial diagnostic test after clinical examination is B-scan ultrasonography, particularly when corneal opacity, hypopyon, or vitreous haze prevent direct visualization of the posterior segment. B-scan demonstrates the extent of vitreous involvement and can detect retinal detachment, choroidal thickening, and posterior scleral inflammation that hint at extension beyond the globe.

A CT scan of the orbit is ordered when there are clinical signs of orbital extension or when a retained intraocular foreign body is suspected after trauma. CT helps distinguish endophthalmitis from true panophthalmitis by showing inflammatory changes in orbital fat and around the extraocular muscles. MRI is reserved for evaluating suspected cavernous sinus or intracranial extension.

The most accurate test (gold standard) for microbiological confirmation is a vitreous tap with culture and Gram stain. Vitreous yields a higher diagnostic rate than aqueous because it harbors a larger bacterial load. The tap is performed in the operating room under sterile conditions, and intravitreal antibiotics are injected at the same sitting. In endogenous cases, blood cultures are required to identify the primary source, and additional workup looks for endocarditis (echocardiography), urinary tract infection, or liver abscess.

Routine workup also includes a complete blood count, blood glucose (diabetes is a major risk factor for endogenous infection), HIV testing where appropriate, and inflammatory markers to monitor response to therapy.

04Management and Treatment

The cornerstone of acute management is immediate intravitreal antibiotic injection combined with systemic antibiotics. Empirical intravitreal therapy uses vancomycin 1 mg in 0.1 mL to cover gram-positive organisms (including methicillin-resistant Staphylococcus) plus ceftazidime 2.25 mg in 0.1 mL to cover gram-negative organisms including Pseudomonas. An alternative for ceftazidime in penicillin-allergic patients is amikacin 0.4 mg in 0.1 mL, although aminoglycoside retinal toxicity limits its use. Injections may be repeated every 48 to 72 hours based on clinical response.

Unlike isolated endophthalmitis, where systemic antibiotics are sometimes deferred, panophthalmitis always requires intravenous antibiotics because orbital and systemic involvement places the patient at risk for cavernous sinus thrombosis and meningitis. Standard regimens use IV vancomycin (15 to 20 mg/kg every 8 to 12 hours) plus IV ceftazidime (1 to 2 g every 8 hours), continued for 10 to 14 days and adjusted based on culture results.

Adjunctive measures include topical fortified antibiotics applied hourly, cycloplegic drops (atropine 1% three times daily) to relieve ciliary spasm and prevent posterior synechiae, and analgesia. Topical and oral corticosteroids may be added 48 hours after starting antibiotics in confirmed bacterial cases to reduce inflammation, but they are contraindicated until fungal etiology has been excluded.

When fungal panophthalmitis is confirmed (Candida or Aspergillus), treatment shifts to intravitreal voriconazole 100 mcg in 0.1 mL plus systemic voriconazole or amphotericin B. Steroids must be avoided in this setting.

The "next best step" question on examinations often asks what to do when vision deteriorates to no light perception despite optimal antibiotic therapy, or when the globe is clearly destroyed. The answer is evisceration (removal of intraocular contents leaving the scleral shell intact) or enucleation (removal of the entire globe). Evisceration is generally preferred because it preserves orbital anatomy for a better prosthetic outcome, but enucleation is mandatory when an underlying intraocular tumor (such as retinoblastoma) is suspected, since evisceration risks tumor seeding.

In pregnancy, both vancomycin and ceftazidime are acceptable. Aminoglycosides should be avoided due to fetal ototoxicity. Voriconazole is contraindicated in pregnancy because of teratogenicity, and amphotericin B is the preferred antifungal. In renal failure, vancomycin and ceftazidime doses must be adjusted based on creatinine clearance.

05Differential Diagnosis and Distractors

The most common pitfall is failing to separate endophthalmitis from panophthalmitis. The vignette will provide a clue: if proptosis, lid swelling, restricted motility, or systemic signs (fever, leukocytosis) are mentioned, the answer is panophthalmitis. If the inflammation is confined to the eye with no orbital involvement, the answer is endophthalmitis.

Another classic distractor is orbital cellulitis. The discriminator is that vision is preserved early in orbital cellulitis (until optic nerve compression develops) and there is no hypopyon or vitritis. In panophthalmitis, intraocular signs (hypopyon, absent red reflex) coexist with orbital signs.

06Traps and High-Yield Pearls

The most frequent trap in panophthalmitis questions is treating the diagnosis as if it were ordinary endophthalmitis. Test writers exploit this by giving a patient with a recent penetrating injury who initially had endophthalmitis but now presents with proptosis, ophthalmoplegia, lid edema, and fever. Students who answer "intravitreal vancomycin and ceftazidime alone" miss the point that systemic involvement now mandates intravenous antibiotics and consideration of evisceration.

A second high-yield trap involves the eviscerate versus enucleate decision. If the question describes a child with leukocoria and a painful, opaque eye, the answer is enucleation, not evisceration, because of the risk of seeding an underlying retinoblastoma. In adults with no suspicion of tumor and a blind, painful eye after fulminant infection, evisceration is the correct procedure.

A third common pitfall is the organism-trauma association. Penetrating trauma with vegetable or soil contamination strongly suggests Bacillus cereus, an organism notorious for fulminant globe destruction within 24 to 48 hours. Recognizing this scenario should prompt immediate surgical and antibiotic intervention rather than observation.

A fourth pearl concerns the endogenous case. When panophthalmitis develops without trauma or surgery, the question is testing whether you remember to look for a systemic source. Diabetic patients with liver abscess (Klebsiella pneumoniae), patients with infective endocarditis, and intravenous drug users are the typical scenarios. The workup must include blood cultures, echocardiography, and abdominal imaging.

Finally, the underlying competency being tested is prompt recognition of an orbital and intraocular emergency that threatens both the eye and the brain. The exam wants you to recognize the constellation of intraocular suppuration plus orbital signs, initiate intravitreal and intravenous antibiotics without delay, and identify the threshold for surgical removal of the globe to prevent intracranial spread.